SCHEMBL13538985

SCHEMBL13538985

O=Cc1nc(-c2c[nH]c3ncc(Br)cc23)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.48
▸ CDK1 P06493 2/20 0.48
▸ PLK4 O00444 1/20 0.48
▸ AURKA O14965 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ ROCK2 O75116 1/20 0.48
▸ PRKD3 O94806 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ PRKCG P05129 1/20 0.48
▸ INSR P06213 1/20 0.48
▸ FES P07332 1/20 0.48
▸ IGF1R P08069 1/20 0.48
▸ ROS1 P08922 1/20 0.48
▸ FGFR1 P11362 1/20 0.48
▸ PHKG2 P15735 1/20 0.48
▸ FER P16591 1/20 0.48
▸ FLT1 P17948 1/20 0.48
▸ MARK3 P27448 1/20 0.48
▸ FLT4 P35916 1/20 0.48
▸ KDR P35968 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1516690 0.82 PDPK1 (0.57) CDK2CDK1PLK4AURKAJAK2
Bromide SCHEMBL1516571 0.81 PDPK1 (0.56) CDK2CDK1PLK4AURKAJAK2
SCHEMBL1801591 0.81 PDPK1 (0.53) CDK2CDK1PLK4AURKAJAK2
SCHEMBL13539023 0.79 ROCK1 (0.39) CDK2JAK2PRKCGFLT3IRAK1
SCHEMBL1799923 0.79 DYRK1A (0.50) CDK2CDK1PLK4AURKAJAK2
SCHEMBL13539068 0.78 PDPK1 (0.39) CDK2JAK2PRKCGFLT3IRAK1
SCHEMBL9279751 0.75 JAK2 (0.55) CDK2CDK1PLK4AURKAJAK2
SCHEMBL1800868 0.75 PDPK1 (0.53) CDK2CDK1PLK4AURKAJAK2
SCHEMBL13505098 0.74 MAP4K4 (0.44) CDK2CDK1PLK4AURKAJAK2
SCHEMBL13888049 0.74 ROCK1 (0.55) CDK2CDK1PLK4AURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645769-B2 Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-01-12 — — US disclosed
Send feedback